CEO of Dogwood Therapeutics (DWTX) receives 330,000 stock option grant

Rhea-AI Filing Summary

Duncan Gregory Scott reported acquisition or exercise transactions in this Form 4 filing.

Dogwood Therapeutics, Inc. reported that Chief Executive Officer and director Duncan Gregory Scott received a grant of stock options covering 330,000 shares on March 5, 2026. The options vest one‑third on March 5, 2027 and then in 1/24th monthly installments thereafter.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Duncan Gregory Scott

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	330,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 330,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duncan Gregory Scott

(Last) (First) (Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA GA 30009

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.86	03/05/2026		A		330,000		(1)	03/05/2036	Common Stock	330,000	$0	330,000	D

Explanation of Responses:

1. The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

	/s/ Greg Duncan	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dogwood Therapeutics (DWTX) report for Duncan Gregory Scott?

Dogwood Therapeutics reported that CEO and director Duncan Gregory Scott received a grant of stock options for 330,000 shares on March 5, 2026. This is recorded as an acquisition under a Form 4 insider filing for derivative securities.

How many stock options were granted to the Dogwood Therapeutics (DWTX) CEO?

The Dogwood Therapeutics CEO, Duncan Gregory Scott, was granted stock options covering 330,000 shares. These options increase his direct derivative holdings to 330,000 following the transaction, according to the Form 4 insider trading report.

What is the vesting schedule for Duncan Gregory Scott’s Dogwood Therapeutics (DWTX) stock options?

The stock options granted to Duncan Gregory Scott vest one-third on March 5, 2027. The remaining two-thirds then vest in 1/24th monthly installments thereafter, creating a multi-year vesting period tied to continued service.

Is the Dogwood Therapeutics (DWTX) Form 4 transaction a purchase or a grant?

The Form 4 transaction is reported as a grant or award acquisition of derivative securities, not an open-market purchase. It reflects stock options awarded to CEO Duncan Gregory Scott rather than him buying shares on the market.

Does Duncan Gregory Scott hold the Dogwood Therapeutics (DWTX) options directly or indirectly?

The Form 4 indicates that Duncan Gregory Scott holds the 330,000 Dogwood Therapeutics stock options as a direct ownership position. The ownership code is marked as direct, with no indirect holding entity noted in the disclosure.